KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $6.6 million.

  • Novavax's Depreciation & Amortization (CF) fell 4814.96% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year decrease of 2515.98%. This contributed to the annual value of $48.5 million for FY2024, which is 1763.74% up from last year.
  • Novavax's Depreciation & Amortization (CF) amounted to $6.6 million in Q3 2025, which was down 4814.96% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Depreciation & Amortization (CF) ranged from a high of $12.7 million in Q3 2024 and a low of $2.3 million during Q1 2021
  • Over the past 5 years, Novavax's median Depreciation & Amortization (CF) value was $8.3 million (recorded in 2025), while the average stood at $8.1 million.
  • As far as peak fluctuations go, Novavax's Depreciation & Amortization (CF) skyrocketed by 19197.24% in 2022, and later crashed by 4814.96% in 2025.
  • Over the past 5 years, Novavax's Depreciation & Amortization (CF) (Quarter) stood at $3.7 million in 2021, then skyrocketed by 96.68% to $7.2 million in 2022, then skyrocketed by 49.46% to $10.8 million in 2023, then increased by 15.96% to $12.5 million in 2024, then crashed by 47.39% to $6.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $6.6 million in Q3 2025, compared to $7.6 million in Q2 2025 and $8.3 million in Q1 2025.